Analysis of Nucleoporin 107 Overexpression and Its Association with Prognosis and Immune Infiltration in Lung Adenocarcinoma by Bioinformatics Methods

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378(9804):1727–1740. doi:10.1016/S0140-6736(10)62101-0
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630
   PubMed Web of Science ®Google Scholar
• Macheleidt IF, Dalvi PS, Lim SY, et al. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations. Mol Oncol. 2018;12(11):1965–1979. doi:10.1002/1878-0261.12382
   PubMed Web of Science ®Google Scholar
• Shi R, Xu L, Huang L, Cheng JX. Nucleoporin 107 promotes the survival of tumor cells in cervical cancers. Gynecol Obstet Invest. 2020;85(1):41–52. doi:10.1159/000502788
   PubMed Web of Science ®Google Scholar
• Nong JS, Zhou X, Liu JQ, et al. Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration. Cancer Med. 2023;12(9):10990–11009. doi:10.1002/cam4.5807
   PubMed Web of Science ®Google Scholar
• Alanee S, Delfino K, Wilber A, Robinson K, Brard L, Semaan A. Single nucleotide variant in nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer. Pharmacogenet Genomics. 2017;27(7):264–269. doi:10.1097/FPC.0000000000000288
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinf. 2008;9(1):559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Chen D, Wang M, Jiang X, Xiong Z. Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: from gastric adenocarcinoma to pan-cancers. Discov Oncol. 2022;13(1):24. doi:10.1007/s12672-022-00487-0
   PubMedGoogle Scholar
• Liu G, Wu X, Chen J. Identification and validation of a glycolysis-related gene signature for depicting clinical characteristics and its relationship with tumor immunity in patients with colon cancer. Aging. 2022;14(21):8700–8718. doi:10.18632/aging.204226
   PubMedGoogle Scholar
• Liu J, Peng Y, Wei W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2022;32(1):30–44. doi:10.1016/j.tcb.2021.07.001
   PubMed Web of Science ®Google Scholar
• Wang WH, Ma CG, Cui YS, et al. Role of prognostic marker PRR11 in immune infiltration for facilitating lung adenocarcinoma progression. Biomed Environ Sci. 2023;36(9):862–868. doi:10.3967/bes2023.111
   PubMed Web of Science ®Google Scholar
• Yin Y, He M, Huang Y, Xie X. Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma. BMC Immunol. 2023;24(1):37. doi:10.1186/s12865-023-00572-1
   PubMed Web of Science ®Google Scholar
• Anttila S, Raunio H, Hakkola J. Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. Am J Respir Cell Mol Biol. 2011;44(5):583–590. doi:10.1165/rcmb.2010-0189RT
   PubMed Web of Science ®Google Scholar
• McCarty MF, DiNicolantonio JJ. Minimizing membrane arachidonic acid content as a strategy for controlling cancer: a review. Nutr Cancer. 2018;70(6):840–850. doi:10.1080/01635581.2018.1470657
   PubMed Web of Science ®Google Scholar
• Qiu A, Xu H, Mao L, et al. A novel apaQTL-SNP for the modification of non-small-cell lung cancer susceptibility across histological subtypes. Cancers. 2022;14(21):5309. doi:10.3390/cancers14215309
   PubMed Web of Science ®Google Scholar
• Kou F, Sun H, Wu L, et al. TOP2A promotes lung adenocarcinoma cells’ malignant progression and predicts poor prognosis in lung adenocarcinoma. J Cancer. 2020;11(9):2496–2508. doi:10.7150/jca.41415
   PubMed Web of Science ®Google Scholar
• Nie Z, Pu T, Han Z, et al. Extra spindle pole bodies-like 1 serves as a prognostic biomarker and promotes lung adenocarcinoma metastasis. Front Oncol. 2022;12:930647. doi:10.3389/fonc.2022.930647
   PubMed Web of Science ®Google Scholar
• Wang L, Yang X, An N, Liu J. Bioinformatics analysis of BUB1 expression and gene regulation network in lung adenocarcinoma. Transl Cancer Res. 2020;9(8):4820–4833. doi:10.21037/tcr-20-1045
   PubMed Web of Science ®Google Scholar
• Qiao Y, Chen J, Ma C, et al. Increased KIF15 expression predicts a poor prognosis in patients with lung adenocarcinoma. Cell Physiol Biochem. 2018;51(1):1–10. doi:10.1159/000495155
   PubMedGoogle Scholar
• Yi M, Li T, Qin S, et al. Identifying tumorigenesis and prognosis-related genes of lung adenocarcinoma: based on weighted gene coexpression network analysis. Biomed Res Int. 2020;2020:4169691. doi:10.1155/2020/4169691
   PubMed Web of Science ®Google Scholar
• Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310. doi:10.3390/ijms19051310
   PubMed Web of Science ®Google Scholar
• Su K, Wang N, Shao Q, Liu H, Zhao B, Ma S. The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression. Biomed Pharmacother. 2021;137:111389. doi:10.1016/j.biopha.2021.111389
   PubMed Web of Science ®Google Scholar
• Tan X, Qin W, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011;17(21):6802–6811. doi:10.1158/1078-0432.CCR-11-0419
   PubMed Web of Science ®Google Scholar
• Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32. doi:10.1016/j.ctrv.2018.02.004
   PubMed Web of Science ®Google Scholar
• Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019;16(1):6–18. doi:10.1038/s41423-018-0027-x
   PubMed Web of Science ®Google Scholar
• Wylie B, Macri C, Mintern JD, Waithman J. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers. 2019;11(4). doi:10.3390/cancers11040521
   Web of Science ®Google Scholar
• Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1–2):5–17. doi:10.1038/s41417-020-0183-x
   PubMed Web of Science ®Google Scholar
• He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genomics. 2019;18(2):99–106. doi:10.1093/bfgp/ely006
   PubMed Web of Science ®Google Scholar
• Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable? Curr Med Chem. 2016;23(7):650–666. doi:10.2174/0929867323666160119094313
   PubMed Web of Science ®Google Scholar
• Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new Dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594–607. doi:10.1038/s41568-020-0283-9
   PubMed Web of Science ®Google Scholar
• Najafi M, Hashemi Goradel N, Farhood B, et al. Macrophage polarity in cancer: a review. J Cell Biochem. 2019;120(3):2756–2765. doi:10.1002/jcb.27646
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424. doi:10.3389/fimmu.2017.00424
   PubMed Web of Science ®Google Scholar
• Bao X, Shi R, Zhao T, Wang Y. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma. Mol Oncol. 2020;14(5):917–932. doi:10.1002/1878-0261.12670
   PubMed Web of Science ®Google Scholar
• Niogret J, Berger H, Rebe C, et al. Follicular helper-T cells restore CD8 + -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J Immunother Cancer. 2021;9(6):e002157. doi:10.1136/jitc-2020-002157
   PubMed Web of Science ®Google Scholar
• Duan MC, Zhong XN, Liu GN, Wei JR. The Treg/Th17 paradigm in lung cancer. J Immunol Res. 2014;2014:730380. doi:10.1155/2014/730380
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Memon H, Patel BM. Immune checkpoint inhibitors in non-small cell lung cancer: a bird’s eye view. Life Sci. 2019;233:116713. doi:10.1016/j.lfs.2019.116713
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798. doi:10.3389/fphar.2021.731798
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001
   PubMed Web of Science ®Google Scholar
• De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The landscape of immunotherapy in advanced NSCLC: driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines). Curr Oncol Rep. 2021;23(11):126. doi:10.1007/s11912-021-01124-9
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917–927. doi:10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108–119. doi:10.1111/cei.13407
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi:10.1038/s41568-019-0116-x
   PubMed Web of Science ®Google Scholar